The current role of gemcitabine in ovarian cancer

Seminars in Oncology

Volumn 28, Issue 2 SUPPL. 7, 2001, Pages 18-24

  Ozols, Robert F ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

EID: 0035006911     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.24368     Document Type: Review

References (21)

1. Cancer Facts and Figures—2000. Atlanta, GA, American Cancer Society;
2. http://www.cancer.org/
3. WP McGuire WJ Hoskins MF Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
4. MJ Piccart K Bertelsen K James Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclo-phosphamide in women with advanced epithelial ovarian cancer: Three-year results J Natl Cancer Inst 92 2000 699 708
5. FM Muggia PS Braly MF Brady Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study J Clin Oncol 18 2000 106 115
6. RF Ozols BN Bundy J Fowler Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 158) Proceedings of the annual meeting of the Society of Gynecologic Oncologists abstr 100158 2000
7. A du Bois HJ Lueck W Meier Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group trial Proc Am Soc Clin Oncol 18 1999 356a (abstr 1374)
8. P Harper A randomised comparison of paclitaxel (T) and carboplatin (J) versus a control arm of single agent carboplatin (J) or CAP (cyclophosphamide, doxorubicin and cisplatin): 2075 patients randomised into the 3rd International Collaborative Ovarian Neoplasm Study (ICON3) Proc Am Soc Clin Oncol 18 1999 356a (abstr 1375)
9. RF Ozols The role of gemcitabine in the treatment of ovarian cancer Semin Oncol 27 2000 40 47
10. RF Ozols Update of the NCCN ovarian cancer practice guidelines Oncology (Huntingt) 11 1997 95 105
11. B Lund OP Hansen K Theilade Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients J Natl Cancer Inst 86 1994 1530 1533
12. JD Shapiro MJ Millward D Rischin Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel Gynecol Oncol 63 1996 89 93
13. M Coenen P Verteloot F Amant Gemcitabine in platin-paclitaxel resistant ovarian carcinoma Proc Am Soc Clin Oncol 19 2000 405a (abstr 1603)
14. Markman M. Personal communication, 2000
15. M Orlando J Nadal RD Chacon Gemcitabine (G) and carboplatin (C) in patients (Pts) with relapsed ovarian cancer (ROC): A phase I–II study Proc Am Soc Clin Oncol 19 2000 403a (abstr 1594)
16. CJ Poole T Perren T Hogberg Phase I study to investigate the optimal dose and schedule of gemcitabine (G) and paclitaxel (P) in combination in patients with previously treated epithelial ovarian cancer Proc Am Soc Clin Oncol 17 1998 357a (abstr 1380)
17. SE Lentz AA Garcia M Bookman Phase I trial of gemcitabine and protracted oral etoposide in recurrent gynecological tumors: A Gynecologic Oncology Group study Proc Am Soc Clin Oncol 19 2000 405a (abstr 1604)
18. DH Tobias C Runowicz J Mandeli A phase I trial of gemcitabine and Doxil for recurrent epithelial ovarian cancer Proc Am Soc Clin Oncol 19 2000 392a (abstr 1551)
19. C Underhill FX Parnis M Highley A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer (EOC) Ann Oncol 7 1996 69 (abstr 3240)
20. M Nogué L Cirera M Arcusa Gemcitabine combined with cisplatin first line: A phase II study in patients with advanced epithelial ovarian cancer Proc Am Soc Clin Oncol 17 1998 357a (abstr 1377)
21. SW Hansen H Anderson K Boman Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV Proc Am Soc Clin Oncol 18 1999 357a (abstr 1379)